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Summary
Background Cerebral cavernous malformations (CCMs) are prone to bleeding but the risk of intracranial haemorrhage 
and focal neurological deﬁ cits, and the factors that might predict their occurrence, are unclear. We aimed to quantify 
these risks and investigate whether they are aﬀ ected by sex and CCM location.
Methods We undertook a population-based study using multiple overlapping sources of case ascertainment (including 
a Scotland-wide collaboration of neurologists, neurosurgeons, stroke physicians, radiologists, and pathologists, as 
well as searches of registers of hospital discharges and death certiﬁ cates) to identify deﬁ nite CCM diagnoses ﬁ rst 
made in Scottish residents between 1999 and 2003, which study neuroradiologists independently validated. We used 
multiple sources of prospective follow-up both to identify outcome events (which were assessed by use of brain 
imaging, by investigators masked to potential predictive factors) and to assess adults’ dependence. The primary 
outcome was a composite of intracranial haemorrhage or focal neurological deﬁ cits (not including epileptic seizure) 
that were deﬁ nitely or possibly related to CCM.
Findings 139 adults had at least one deﬁ nite CCM and 134 were alive at initial presentation. During 1177 person-years 
of follow-up (completeness 97%), for intracranial haemorrhage alone the 5-year risk of a ﬁ rst haemorrhage was lower 
than the risk of recurrent haemorrhage (2·4%, 95% CI 0·0–5·7 vs 29·5%, 4·1–55·0; p<0·0001). For the primary 
outcome, the 5-year risk of a ﬁ rst event was lower than the risk of recurrence (9·3%, 3·1–15·4 vs 42·4%, 26·8–58·0; 
p<0·0001). The annual risk of recurrence of the primary outcome declined from 19·8% (95% CI 6·1–33·4) in year 1 
to 5·0% (0·0–14·8) in year 5 and was higher for women than men (p=0∙01) but not for adults with brainstem CCMs 
versus CCMs in other locations (p=0∙17).
Interpretation The risk of recurrent intracranial haemor rhage or focal neurological deﬁ cit from a CCM is greater than 
the risk of a ﬁ rst event, is greater for women than for men, and declines over 5 years. This information can be used in 
clinical practice, but further work is needed to quantify risks precisely in the long term and to understand why 
women are at greater risk of recurrence than men.
Funding UK Medical Research Council, Chief Scientist Oﬃ  ce of the Scottish Government, and UK Stroke Association.
Introduction
Cerebral cavernous malformations (CCMs) are common, 
occurring in one in about 600 neurologically asymp-
tomatic people as evident on MRI scans and one in about 
200 patients in hospital-based MRI or autopsy series.1–5 
Population-based annual CCM detection rates were 
0·17 (95% CI 0·00–0·34) per 100 000 people in the USA 
from 1965 to 1992 compared with 0·56 (0·41–0·75) per 
100 000 in Scotland from 1999 to 2000;6,7 this diﬀ erence in 
detection rates might be partly explained by the increasing 
availability and use of brain MRI. CCMs can be sporadic 
or inherited as an autosomal dominant trait,8 in which 
multiple CCMs occur, and appear de novo.9
CCMs are blood vessels devoid of muscular and elastic 
tissue that are lined with endothelial cells that do not 
have intervening tight junctions. CCMs are prone to 
haemorrhage,10 which results in distinctive diagnostic 
appearances on pathological examination and MRI.10–12 
Of CCMs diag nosed in adults on the basis of neurological 
symptoms, one quarter are identiﬁ ed owing to 
intracranial haemor rhage and another quarter are 
identiﬁ ed after a focal neurological deﬁ cit without 
radiographic evidence of recent haemorrhage;13 the 
remainder of patients present with epileptic seizures.14 
Hospital-based case series have described the untreated 
clinical course of CCMs during mostly retrospective 
observation, with means of 1·9–5·2 years follow-up. In 
these studies, inception points (ie, the start of follow-
up), diagnostic criteria, outcome deﬁ nitions, and 
methods of assessment and analysis varied (ﬁ gure 1 and 
webappendix pp 1–3).3,5,12,15–25 In these studies, the annual 
risk of ﬁ rst intracranial haemorrhage (range 
0·4–0·6%)16,17 and the annual risk of recurrent intra-
cranial haemorrhage (3·8–22·9%)3,16,17,21 varied (ﬁ gure 1). 
Patients with brainstem CCM seem to have a higher 
risk of recurrent intracranial haemorrhage when 
indirectly compared with cohorts of patients with CCM 
in other brain regions (21·0–60·2%; ﬁ gure 1),15,20,22,24 
although internal comparisons within individual cohorts 
have not conﬁ rmed this ﬁ nding.17,21 Findings have not 
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been consistent regarding whether female sex is 
associated with incident haemorrhage5,16 or not,19 or with 
recurrent intracranial haemorrhage16,19 or not.17,18,21 
Intracranial haemorrhage from a CCM tends to be 
intracerebral and of low volume,26 although case fatality 
has ranged from 0% overall18 to 17% for recurrent 
haemorrhage from brainstem CCMs.15 Little is known 
about the eﬀ ect of intracranial haemorrhage or non-
haemorrhagic focal neurological deﬁ cits on survivors’ 
functional outcome.18,27,28
Therefore, we investigated the risks, predictors, and 
functional eﬀ ect of intracranial haemorrhage and non-
haemorrhagic focal neurological deﬁ cits in a prospective, 
population-based cohort study. We planned to report 
outcomes at 5 years to encourage standardisation of out-
come reporting for CCMs,13 and we aimed to stratify 
survival analyses by mode of initial CCM presentation. 
We hypothesised that female sex and brainstem CCM 
location would also predict poor outcome.
Methods
Patients
The Scottish Audit of Intracranial Vascular Malformations 
(SAIVMs) is an ongoing National Health Service clinical 
audit of adults who were aged 16 years or older and 
were resident in Scotland when ﬁ rst diagnosed with 
any type of intracranial vascular malformation during 
1999–2003 and 2006–2010. The Scottish Intracranial 
Vascular Malformations Study (SIVMS) is a prospective, 
population-based cohort study in which we used 
anonymous data extracts from SAIVMs. We have 
published the audit protocol and registered the research 
protocol with the Directory of Clinical Databases 
(DoCDat). Patients were identiﬁ ed through multiple 
overlapping sources of case ascertain ment, which 
included a Scotland-wide collaborative network of 
neurologists, neurosurgeons, stroke physicians, radio-
logists, and pathologists and central registers of hospital 
discharge records and death certiﬁ cates.7 In this analysis, 
we included every adult in SIVMS who had a ﬁ rst-in-a-
lifetime deﬁ nite diagnosis of CCM in the years 
1999–2003, made on the basis of pathological examination 
or brain MRI.11,12 
The Multicentre Research Ethics Committee for 
Scotland (MREC/98/0/48) and the Fife and Forth Valley 
Research Ethics Committee (08/S0501/76) approved the 
under taking of observational studies (to which an opt-out 
consent policy applied) and postal questionnaire studies 
(which required opt-in consent).
Procedures
The inception point was an adult’s initial presentation, 
which was the date of symptom onset or medical 
consultation (if asymptomatic) that led to an investigation 
that diagnosed a CCM. We used annual surveillance of 
family doctor and hospital medical records, as well as 
annual postal questionnaires to family doctors and 
consenting participants with a CCM on each anniversary 
of CCM diagnosis, to establish demographics and 
medical histories, to identify outcome events, and to 
assess adults’ dependence (by the Oxford Handicap Scale 
[OHS]) prospectively during follow-up.29
Two neuroradiologists (JJB and RJS) used the diagnostic 
brain images that had been obtained in clinical practice 
to verify CCM diagnosis with reference to accepted 
criteria11,12 and collected data on CCM anatomical location, 
CCM size, coexistent intracranial vascular malformations, 
and radiological evidence for recent intracranial haemor-
rhage.13 We also reviewed brain imaging and reports of 
pathological examinations to classify the mode of initial 
CCM presentation. Two investigators (CPW and RA-SS) 
assessed outcome events using the clinical, radiological, 
and pathological information available, masked to sex 
and CCM location. To attribute the mode and cause of 
death, we reviewed death certiﬁ cates, autopsy reports if 
post-mortem examination had been done, and clinical 
records and pertinent brain images if death had occurred 
during a hospital stay.
We used published criteria to distinguish intracranial 
haemorrhage, non-haemorrhagic focal neurological deﬁ -
cits (if timely brain imaging of the appropriate modality 
had not identiﬁ ed fresh haemorrhage), and focal 
neurological deﬁ cits not otherwise speciﬁ ed (if timely 
brain imaging of the appropriate modality had not been 
done).13 We regarded initial presentations as incidental if 
the adult had been asymptomatic or if their symptoms 
First or recurrent intracranial haemorrhage    
Robinson et al,5 1991 None 66 2·2
Zabramski et al,12 1994 Familial 21 2·2
Porter et al,18 1997 None 110 3·8
Moriarity et al,19 1999 None 68 5·2
Ghannane et al,25 2007 None 39 2·5
First intracranial haemorrhage     
Aiba et al,16 1995 None 110 4·7
Kondziolka et al,17 1995 None 122 2·8
Mathiesen et al,23 2003 Brainstem or deep 34 4·6
Recurrent intracranial haemorrhage     
Aiba et al,16 1995 None 110 4·7
Kondziolka et al,17 1995 None 122 2·8
Kim et al,3 1997 None 62 1·9
Barker et al,21 2001 None 136 3·8
Fritschi et al,15 1994 Brainstem 139 2·5
Porter et al,20 1999 Brainstem 100 2·0
Hasegawa et al,22 2002 Brainstem 83 4·3
Wang et al,24 2003 Brainstem 137 1·8
Mathiesen et al,23 2003 Brainstem or deep 34 4·6
Selection criteria Sample Mean follow-up 
 size (years)
0 10 20 30 40
Intracranial haemorrhage rate (%/year)
50 60 70
Figure 1: Risk of symptomatic intracranial haemorrhage during follow-up in studies of the untreated clinical 
course of over 20 participants with cerebral cavernous malformations
Areas of point estimates are proportional to the sample size of each study. Error bars represent 95% CIs (if available 
or calculable).
For the SAIVMs website see 
http://www.saivms.scot.nhs.uk 
For the SAIVMs protocol see 
http://www.saivms.scot.nhs.uk/
pdf/2008_06_SAIVMs%20
protocol_v2.pdf
For the DoCDat see http://www.
icapp.nhs.uk/docdat/
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(eg, headache) could not be related to the underlying 
CCM. We attributed initial presentations to epileptic 
seizures if the seizures were not symptomatic of a 
concomitant intracranial haemorrhage. When assessing 
clinical events at initial presentation and during follow-
up, we also classiﬁ ed whether they were deﬁ nitely, 
possibly, or deﬁ nitely not attributable to the CCM. We 
classiﬁ ed events as possibly attributable to a CCM when 
the clinical features of an event were anatomically 
consistent with CCM location, but another cause 
(eg, ischaemic stroke) was possible and neuroradiological 
investigation had not identiﬁ ed either CCM haemorrhage 
or an alternative cause.
The primary outcome was a composite of intracranial 
haemorrhage or focal neurological deﬁ cit because their 
severities seem to be similar26 and many focal neuro-
logical deﬁ cits might be haemorrhages undetected by 
imaging.13 We quantiﬁ ed intracranial haemorrhage alone 
to facilitate comparison with other studies, but chose a 
composite primary outcome to show all the neurological 
deﬁ cits experienced by patients. The primary outcome 
combined events deﬁ nitely attributable to a CCM with 
those possibly attributable because of the absence of a 
better alternative explanation.13 We have described the 
occurrence of seizures after a diagnosis of CCM in this 
cohort elsewhere.14
Statistical analysis
We categorised CCM location as brainstem (in the 
midbrain, pons, or medulla), cerebellar, deep (in the 
thalamus or basal ganglia), or lobar (in the cortex or 
subcortical areas of the cerebral hemispheres). We 
dichotomised location into brainstem versus other 
locations for univariate analyses; if an adult had many 
CCMs, we allocated a primary location according to the 
location of the symptomatic CCM, but in asymptomatic 
adults the brainstem CCM location took precedence 
because it was postulated to be a predictor of intracranial 
haemorrhage or focal neuro logical deﬁ cit. We used 
parametric statistics for between-group comparisons 
when the data obeyed a normal distribution and non-
parametric statistics when they did not. We used exact 
tests when cell counts were fewer than ﬁ ve.
We quantiﬁ ed completeness of the follow-up data we 
had accrued as a proportion of all the follow-up that 
could have been obtained before death or the end of the 
5-year timeframe for these analyses.30 We used life tables 
and Kaplan-Meier estimates together with log-rank tests 
to analyse follow-up data accrued by February, 2011. 
Survival analyses of time to ﬁ rst event for adults who 
were event-free at presentation started at the date of 
initial presentation and stopped at the date of the ﬁ rst 
outcome event or the date of censoring, whichever 
occurred ﬁ rst. Survival analyses of time to earliest 
recurrent event started at the date of the ﬁ rst event 
(whether it occurred at initial presentation or during 
follow-up) and stopped at the date of the earliest 
recurrent outcome or the date of censoring, whichever 
occurred ﬁ rst. We censored follow-up at the earliest 
occurrence of any of the following: death unrelated to 
CCM, ﬁ rst CCM treatment (with surgical excision or 
stereotactic radio surgery, at the discretion of the treating 
physician), last available follow-up, or 5 years after initial 
presentation.
We stratiﬁ ed survival analyses by mode of initial CCM 
presentation. We investigated the eﬀ ect of two potential 
predictors: men versus women and brainstem versus 
other CCM primary locations. We prespeciﬁ ed these 
factors on the basis of their clinical relevance and 
their hypothesised eﬀ ect on outcome, as well as on the 
accuracy, reliability, and completeness of their ascertain-
ment. We did univariate comparisons with the log-rank 
test, quantiﬁ ed survival functions at 5 years, and did Cox 
regression if proportional hazards assumptions were 
satisﬁ ed.31 We used sensitivity analyses to assess whether 
restriction of analyses to events deﬁ nitely attributable to 
CCM aﬀ ected our primary outcome analyses.
We did not prespecify our desired sample size, but 
instead we sought to identify every new deﬁ nite CCM 
diagnosis over 5 years in one country (the mid-2010 popu-
lation estimate of adults aged 16 years or older was 
4·31 million)32 and accrue follow-up until we had 
suﬃ  cient outcome events to analyse our two potential 
predictors in multivariable analyses (at least 20 events to 
ﬁ t a multivariable model with two covariates). We used 
two-tailed statistical tests (α=0·05). Analyses were done 
with SPSS (version 16.0), Stata (version 11.2), StatsDirect 
(version 2.7.8), and Conﬁ dence Interval Analysis software 
(version 2.2.0).
Role of the funding source
The study sponsors had no role in study design, in the 
collection, analysis, and interpretation of data, in the 
writing of the report, or in the decision to submit the 
Incidental 
presentation (n=61)
Presentation with epileptic 
seizure or seizures (n=35)
Presentation with ICH 
or FND (n=38)
Age (years) 45 (34–54) 34 (26–46) 38·5 (32·5–56)
Women 38 (62%) 14 (40%) 27 (71%)
Primary CCM location
Lobar 42 (69%) 35 (100%) 13 (34%)
Deep 4 (7%) 0 (0%) 5 (13%)
Cerebellum 10 (16%) 0 (0%) 8 (21%)
Brainstem 5* (8%) 0 (0%) 12 (32%)
Multiple CCMs 6 (10%) 11 (31%) 6 (16%)
Associated 
developmental venous 
anomaly
11 (18%) 1 (3%) 8 (21%)
Data are median (IQR) or number (%). CCM=cerebral cavernous malformation. ICH=intracranial haemorrhage. 
FND=focal neurological deﬁ cit. *Four adults with incidental multiple CCM were allocated a primary brainstem location 
on the basis of the existence of at least one brainstem CCM.
Table: Baseline characteristics of adults who were alive at the time of their diagnosis of cerebral 
cavernous malformations
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paper for publication. The corresponding author had full 
access to all study data and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
From 1999 to 2003, 139 adult residents in Scotland were 
newly diagnosed with at least one deﬁ nite CCM (133 on 
brain MRI, ﬁ ve at autopsy, and one after surgical 
excision). Of these 139 adults, 24 had multiple CCMs, 
20 had associated developmental venous anomalies, two 
had an unrelated intracranial aneurysm, and one had an 
unrelated brain arteriovenous malformation.
The median age of the 139 adults at the initial 
presentation that led to CCM diagnosis was 41 years 
(IQR 32–53 years) and 80 (58%) were women. The 
symptoms leading to CCM diagnosis were incidental 
(n=66, 47%), epileptic seizure (n=35, 25%), intracranial 
haemorrhage (n=17, 12%), and focal neurological deﬁ cits 
(n=21, 15%). The primary CCM locations were lobar 
(n=93, 67%), brainstem (n=19, 14%), cerebellar (n=18, 
13%), and deep (n=9, 6%), and there was no association 
between female sex and CCM location (χ² test, p=0·7).
After omitting the ﬁ ve adults whose CCM (two brain-
stem and three lobar) were ﬁ rst diagnosed inci dentally at 
autopsy and who did not contribute to our outcome 
analyses, we compared 134 adults according to their type 
of initial presentation (table). Adults were older at the 
time of incidental CCM detection than at symp tomatic 
initial presentations (Kruskal Wallis test, p=0·007). 
Adults initially presenting with intracranial haemorrhage 
or focal neurological deﬁ cit were more likely to harbour 
brainstem CCMs (32% vs 5% with other modes of 
presentation, Fisher’s exact test p<0·0001) and seemed to 
be more likely to be women, although this was not 
statistically signiﬁ cant (71% vs 54%, χ² test, p=0·07).
We followed up the 134 adults with CCM who were 
alive at initial presentation for 1177 person-years (of 
1216 potential person-years, for an overall completeness 
of 97%).30 We limited our analyses to the ﬁ rst 5 years of 
follow-up (although years 6 and 7 of follow-up were 
available for this cohort, no outcome events occurred 
during that time). In these analyses, the median duration 
of follow-up per adult was 5 years; of the 17 adults 
followed up for less than 5 years, 15 died within the 
5-year period. Follow-up ended for these 134 adults 
because of censoring at last follow-up (n=97), CCM treat-
ment (n=23, surgical excision in all cases), or death 
unrelated to CCM (n=14). Figure 2 describes the grouping 
of adults in our analyses.
Of 96 adults who initially presented incidentally or with 
seizures, one man and one woman had a ﬁ rst intracranial 
haemorrhage (5-year risk 2·4%, 95% CI 0·0–5·7; 
ﬁ gure 3). Taking together the one survivor of these ﬁ rst 
intracranial haemorrhages during follow-up and the 
17 adults with ﬁ rst intracranial haemorrhage at initial 
presentation, four adults (all women) had a second 
intracranial haemorrhage (5-year risk 29·5%, 4·1–55·0; 
Follow-up (years)
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Figure 3: Kaplan-Meier estimates of progression to ﬁ rst or second intracranial haemorrhage deﬁ nitely 
attributable to cerebral cavernous malformation
ICH=intracranial haemorrhage.
Presentation
First or recurrent ICH deﬁnitely related to CCM
First or recurrent ICH or FND deﬁnitely or possibly related to CCM
61 incidental
 1 ﬁrst fatal ICH*
 1 ﬁrst ICH* and 1 second ICH*
 59 no ICH
35 seizures  35 no ICH
21 ﬁrst FND*  21 no ICH
17 ﬁrst ICH*  3 second ICH*
 14 no further ICH
59 incidental
 1 ﬁrst fatal ICH*
 1 ﬁrst ICH* and 1 second ICH*
 1 ﬁrst FND*
 3 ﬁrst FND†
 1 ﬁrst FND† and 1 second FND†
 52 no further ICH or FND
2 FND†  2 no further ICH or FND
35 seizures  1 ﬁrst FND†
 34 no further ICH or FND
21 ﬁrst FND*
 9 second FND*
 1 second FND†
 11 no further ICH or FND
17 ﬁrst ICH*
 3 second ICH*
 2 FND*
 12 no further ICH or FND
Follow-up
Figure 2: Flowcharts showing the outcomes of adults included in the analyses
ICH=intracranial haemorrhage. FND=focal neurological deﬁ cit. *Event deﬁ nitely 
related to cerebral cavernous malformation. †Event possibly related to cerebral 
cavernous malformation.
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ﬁ gure 3), which was greater than the risk of a ﬁ rst 
intracranial haemorrhage (log-rank p<0·0001). Of all 
23 instances of a ﬁ rst or second haemorrhage, one was 
followed by death within 30 days from a ﬁ rst intracranial 
haemorrhage caused by a lobar CCM (case fatality 4·3%, 
95% CI 0·8–21·0).
For the primary outcome of intracranial haemorrhage 
and focal neurological deﬁ cits (not including epileptic 
seizure) that were deﬁ nitely or possibly related to CCM, 
eight of the 96 adults who initially presented incidentally 
or with seizures had a ﬁ rst event (5-year risk 9·3%, 
95% CI 3·1–15·4; ﬁ gure 4). However, of the 47 adults who 
had, at presentation or during follow-up, a non-fatal ﬁ rst 
intracranial haemorrhage or focal neurological deﬁ cit that 
was deﬁ nitely or possibly related to CCM, 17 had a second 
event (5-year risk 42·4%, 95% CI 26·8–58·0; ﬁ gure 4), 
which was greater than the risk of a ﬁ rst event (log-rank 
p<0·0001). These ﬁ ndings were unchanged in a sensitivity 
analysis that excluded the events that were possibly 
attributable to CCM (webappendix p 4). Three of the 
17 adults who had a second event had further recurrences 
during the follow-up period. The annual risk of a second 
intracranial haemorrhage or focal neurological deﬁ cit that 
was deﬁ nitely or possibly related to CCM declined during 
follow-up: 19·8% (95% CI 6·1–33·4) in year 1, 13·3% 
(0·0–26·4) in year 2, 12·0% (0·0–25·6) in year 3, 4·5% 
(0·0–13·5) in year 4, and 5·0% (0·0–14·8) in year 5. We 
could not detect any statistically signiﬁ cant diﬀ erence in 
functional outcome: after 5 years, there was no diﬀ erence 
in the proportion of adults scoring 0–2 on the OHS after 
ﬁ rst (89%) or second (100%) intracranial haemorrhages 
or focal neurological deﬁ cits that were deﬁ nitely or 
possibly related to CCM (webappendix p 5).
We explored our two prespeciﬁ ed potential predictors 
of a second event for the 47 adults who had a ﬁ rst 
intracranial haemorrhage or focal neurological deﬁ cit 
that was deﬁ nitely or possibly attributable to CCM. The 
risk of a second event was signiﬁ cantly higher for women 
than men (ﬁ gure 5; p=0∙01). In a post-hoc analysis of the 
inﬂ uence of sex on recurrent intracranial haemorrhage 
alone, we found that all four recurrent haemorrhages 
occurred in women but that the diﬀ erence in risk 
between men and women was not statistically signiﬁ cant 
(p=0·29). We did not identify a greater risk for brainstem 
CCM compared with CCM in other locations (p=0∙17; 
webappendix p 6). We were unable to do Cox regression 
involving both sex and CCM location because propor-
tional hazards assumptions were not fulﬁ lled 
(webappendix p 7).31 We assessed the potential for, but 
could not conﬁ rm, confounding between sex and CCM 
location among these 47 adults: of 12 women with 
brainstem CCM, seven (58%) had outcome events; of 
two men with brainstem CCM, one (50%) had an 
outcome event; of 20 women with non-brainstem CCM, 
nine (45%) had outcome events; and of 13 men with 
non-brainstem CCM, none (0%) had an outcome event. 
Multiple CCMs (vs solitary CCM; p=0∙7) and the presence 
of an associated developmental venous anomaly (vs the 
absence of such an anomaly; p=0∙3) did not predict a 
second event during follow-up (data not shown).
Discussion
In this prospective, population-based study of adults 
with CCM, the 5-year risk of a ﬁ rst intracranial 
haemorrhage was lower than the risk of recurrence. 
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Figure 4: Kaplan-Meier estimates of progression to ﬁ rst or second intracranial haemorrhage or focal 
neurological deﬁ cit deﬁ nitely or possibly attributable to cerebral cavernous malformation
ICH=intracranial haemorrhage. FND=focal neurological deﬁ cit.
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neurological deﬁ cit deﬁ nitely or possibly attributable to cerebral cavernous malformation
ICH=intracranial haemorrhage. FND=focal neurological deﬁ cit.
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The diﬀ erence between the risks of ﬁ rst and recurrent 
events was also evident for the primary composite 
endpoint, for which the annual risk of intracranial 
haemorrhage or focal neurological deﬁ cit deﬁ nitely or 
possibly related to CCM was higher for women than 
men and declined signiﬁ cantly over 5 years. We 
conﬁ rmed our prespeciﬁ ed hypothesis that sex 
inﬂ uences the risk of recurrence.
In this study, we minimised several potential sources 
of bias: selection bias, by using a population-based 
design restricted to newly diagnosed cases; detection 
and misclassiﬁ cation biases, by using strict diagnostic 
criteria and outcome deﬁ nitions;11,13 information bias, by 
using prospective follow-up, which attained 97% 
completeness over 5 years; and bias in outcome 
assessment, by masking assessors to potential prognostic 
features.33–35 We followed up each adult for a median of 
5 years and quantiﬁ ed outcomes at 5 years to facilitate 
comparison with future studies;13 we could have 
quantiﬁ ed outcomes over 7 years, but no outcome events 
occurred between 5 and 7 years, which further 
underscores our ﬁ nding of a diminishing annual rate of 
recurrence over time.
Despite identifying all incident CCM diagnoses in an 
adult population over 5 years and assessing the cohort 
for 5 years, the precision of our estimates could be 
improved, and we have addressed this by recently 
identifying a second CCM cohort, results from which 
will be reported in the future. We used clinical 
information and the uncertainties of symptom attri-
bution to CCM inherent in everyday clinical practice to 
enhance the generalisability of our ﬁ ndings,33–35 but we 
might have missed some events by not relying on 
scheduled study visits. Anecdotally, CCM haemorrhage 
can present with epileptic seizure alone, so we might 
have underestimated CCM haemorrhage rates, but 
brain imaging is not used to investigate every seizure in 
clinical practice. Survival analyses include an 
assumption that censoring is not informative, but 
treatment might be related to a patient’s future 
prognosis. In some of our comparisons with log-rank 
tests, a few adults contributed diﬀ erent periods of their 
follow-up time to the two groups being compared. The 
tendency of clinicians to investigate young, normo-
tensive patients with intra cerebral haemor rhage could 
have led to bias in CCM detection in favour of these 
groups.36 The classi ﬁ cation of presenting and outcome 
events as either intracranial haemorrhage or focal 
neurological deﬁ cit depends on the availability and use 
of timely imaging of the appropriate modality, which 
varies between health services. To facilitate comparisons 
with other cohorts, and because both of these clinical 
events are of comparable clinical eﬀ ect and probably 
share the same pathophysiology, we amalgamated them 
in a composite outcome, but work remains to be done 
on the inter-rater and intra-rater reliability of the 
classiﬁ cation of these outcomes.13
The diﬀ erence in risk of recurrence by sex might be 
explained by reporting bias but, as has been found in 
other contexts,37 we think a true diﬀ erence is a more 
likely explanation, which might also have caused the 
possible preponderance of women initially presenting 
with intracranial haemorrhage or focal neurological 
deﬁ cit. Various explanations for this ﬁ nding involve 
biologically plausible mechanisms related to the 
hormonal responsiveness of CCM, due to pregnancy, 
contraception, or hormone replacement therapy.5,16,20,38
Most published studies of CCM prognosis have been 
small, single-centre case series that were potentially 
subject to selection bias, which might explain some of 
the diﬀ erences between these studies (panel). In some 
studies, lifetime event rates have been calculated retro-
spectively assuming CCM presence since birth, but we 
did not include these studies in our systematic review or 
use this technique because CCMs are known to occur de 
novo and might not be congenital.9 Most published 
studies have combined ﬁ rst and recurrent events and 
calculated annualised risks without actuarial analysis 
Panel: Research in context
Systematic review
We used electronic strategies (webappendix p 1) to search 
for journal articles, published before Dec 1, 2011, and 
indexed in OVID Medline and Embase, that described original 
studies of more than 20 adults with cerebral cavernous 
malformations (CCMs) and enumerated symptomatic 
intracranial haemorrhages during a quantiﬁ ed period of 
follow-up. We systematically compared these studies with 
our characteristics of an ideal study of CCM prognosis 
(webappendix pp 2–3).33–35 We extracted the published 
annualised symptomatic intracranial haemorrhage rate from 
each study (or calculated it on the basis of the number of 
symptomatic intracranial haemorrhages occurring during its 
total person-years of follow-up after CCM diagnosis). We also 
extracted the corresponding 95% CI if published (or 
calculated the 95% CI around this incidence rate with 
Conﬁ dence Interval Analysis software, if the necessary data 
had been published), and stratiﬁ ed our presentation of these 
rates in the 14 included studies by mode of initial 
CCM clinical presentation (ﬁ gure 1).3,5,12,15–25
Interpretation
Published studies have quantiﬁ ed variable outcomes for 
adults with CCM according to sex, mode of initial 
presentation, and CCM location (ﬁ gure 1). To our 
knowledge, this is the ﬁ rst cohort study of CCM that is 
prospective, is population-based, and adheres to standards 
recommended for prognosis research.11–13,33–35 We show that 
the risk of recurrent intracranial haemorrhage is an order of 
magnitude greater than the risk of a ﬁ rst haemorrhage, and 
that the risk of a recurrent intracranial haemorrhage or 
focal neurological deﬁ cit is greater for women than men 
and declines over time.
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during follow-up,5,12,18,19,25 which masked the phenomenon 
of diminishing event rate and temporal clustering of 
CCM haemorrhages.21,24
Our ﬁ ndings are important for clinical practice, in 
which patients and their clinicians have to make 
decisions about CCM treatment on the basis of the 
untreated clinical course of CCM and without the 
beneﬁ t of randomised controlled trials. We have shown 
that the risk of a ﬁ rst-ever intracranial haemorrhage is 
low; functional impairment from haemorrhage is mild 
at initial presentation,26 and from our ﬁ ndings it seems 
that further recovery occurs during follow-up and 
30-day case fatality is low. Although the risk of 
recurrence is higher than the risk of a ﬁ rst event, 
especially for women, the risk of recurrence seems to 
decline over time. This decline provides some 
reassurance for patients as time passes without CCM 
treatment after a haemorrhage, and suggests that 
decision making about CCM treatment in clinical 
practice (and in future randomised controlled trials) 
might not need to be compared with the untreated 
clinical course in the long term when event rates may 
be very low.
We, and others, should continue observation of these 
patients over their lifetimes to conﬁ rm the apparent 
decline in risk of recurrent intracranial haemorrhage or 
focal neurological deﬁ cit over time.21,24 Greater precision 
is also needed: the size of our cohort should double with 
the addition of adults diagnosed from 2006 to 2010, and 
we are planning an individual patient data meta-analysis 
with other cohorts. These further studies might improve 
the precision of our estimates and allow conﬁ rmation of 
the predictors that we have identiﬁ ed, assessment of 
other potential predictors, and investigation of why 
women are at a higher risk of recurrence than men.34 
The 5-year event rates and the declining risk of 
recurrence that we have observed will help in the design 
of randomised controlled trials, which hitherto have not 
been conducted for CCM.
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